A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer
- PMID: 19760413
- DOI: 10.1007/s00259-009-1261-3
A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer
Abstract
Purpose: The aim of this study was to determine the range of absorbed doses delivered to thyroid remnants, blood, and red marrow from fixed administrations of radioiodine and to ascertain whether the success of ablation is more dependent on these absorbed doses than on the administered activity.
Methods: Twenty-three patients received 3,000 MBq radioiodine following near-total thyroidectomy. The maximum absorbed dose to remnants was calculated from subsequent single photon emission tomography scans. Absorbed doses delivered to blood and red marrow were calculated from blood samples and from whole-body retention measurements. The protein bound iodine (PBI) was also calculated.
Results: Maximum absorbed doses to thyroid remnants ranged from 7 to 570 Gy. Eighteen of the 23 patients had a successful ablation. A significant difference was seen between the absorbed doses delivered to thyroid remnants, blood, and red marrow for those patients that had a successful ablation compared to those with a failed ablation (p = 0.030, p = 0.043 and p = 0.048, respectively). The difference between the PBI values acquired at day 1 and day 6 were also indicative of response (p = 0.074).
Conclusions: A successful ablation is strongly dependent on the absorbed dose to the thyroid remnant. Dosimetry-based personalized treatment can prevent both sub-optimal administrations, which entails further radioiodine therapy, and excessive administration of radioactivity, which increases the potential for radiation toxicity.
Comment in
-
Can an undetectable value of TG and a negative neck ultrasound study be considered reliable methods to assess the completeness of thyroid ablation?Eur J Nucl Med Mol Imaging. 2010 May;37(5):1039-40; author reply 1041-2. doi: 10.1007/s00259-010-1414-4. Epub 2010 Mar 23. Eur J Nucl Med Mol Imaging. 2010. PMID: 20309685 No abstract available.
Similar articles
-
Whole-remnant and maximum-voxel SPECT/CT dosimetry in 131 I-NaI treatments of differentiated thyroid cancer.Med Phys. 2016 Oct;43(10):5279-5287. doi: 10.1118/1.4961742. Med Phys. 2016. PMID: 28105713
-
Dosimetry in differentiated thyroid carcinoma (12-1402R).Med Phys. 2013 Jan;40(1):012502. doi: 10.1118/1.4769426. Med Phys. 2013. PMID: 23298113
-
Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients. Dosimetry-based model for estimation.Nuklearmedizin. 2015;54(3):137-43. doi: 10.3413/Nukmed-0711-14-12. Epub 2015 May 19. Nuklearmedizin. 2015. PMID: 25987357
-
Efficacy of low-dose iodine-131 ablation of post-operative thyroid remnants: a study of 69 cases.Br J Radiol. 1992 Oct;65(778):905-9. doi: 10.1259/0007-1285-65-778-905. Br J Radiol. 1992. PMID: 1422665 Review.
-
Management of thyroid cancer: radioiodine ablation, "stunning," and treatment of thyroglobulin-positive, (131)I scan-negative patients.Endocr Pract. 2000 Sep-Oct;6(5):401-6. doi: 10.4158/EP.6.5.401. Endocr Pract. 2000. PMID: 11141594 Review.
Cited by
-
Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma.Eur J Nucl Med Mol Imaging. 2010 Apr;37(4):821-8. doi: 10.1007/s00259-010-1398-0. Eur J Nucl Med Mol Imaging. 2010. PMID: 20186542 Review. No abstract available.
-
Cherenkov light emission in molecular radiation therapy of the thyroid and its application to dosimetry.Biomed Opt Express. 2022 Mar 23;13(4):2431-2449. doi: 10.1364/BOE.448139. eCollection 2022 Apr 1. Biomed Opt Express. 2022. PMID: 35519238 Free PMC article.
-
Can an undetectable value of TG and a negative neck ultrasound study be considered reliable methods to assess the completeness of thyroid ablation?Eur J Nucl Med Mol Imaging. 2010 May;37(5):1039-40; author reply 1041-2. doi: 10.1007/s00259-010-1414-4. Epub 2010 Mar 23. Eur J Nucl Med Mol Imaging. 2010. PMID: 20309685 No abstract available.
-
Radioactive iodine therapy: multiple faces of the same polyhedron.Arch Endocrinol Metab. 2022 May 13;66(3):393-406. doi: 10.20945/2359-3997000000461. Epub 2022 May 12. Arch Endocrinol Metab. 2022. PMID: 35551676 Free PMC article. Review.
-
The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patients.Eur J Nucl Med Mol Imaging. 2011 Apr;38(4):673-80. doi: 10.1007/s00259-010-1689-5. Epub 2011 Jan 6. Eur J Nucl Med Mol Imaging. 2011. PMID: 21210115
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical